Presidential Greeting - American Society for Laser Medicine and ...

Q-switched Alexandrite laser (6.5 J/cm 2 ) and 694 nm Ruby laser
(8.4 J/cm 2 ).
Results: Two months later, the areas treated by 755 nm
Alexandrite and 532 nm Q-switched Nd:YAG, and to a lesser
extent, that treated with the 694 nm Q-switched Ruby laser were
significantly paler. There was no appreciable change in the site
treated with the 1,064 nm laser. All lesions were subsequently
treated, at 2-month intervals, with the 755 nm Alexandrite laser.
Treatment was started with a fluency of 6.5 J/cm 2 . At each session,
the fluency was increased as the pigment faded, as tolerated, to a
maximum of 18 J/cm 2 . After four sessions, all treated lesions
showed a lightening in pigmentation by 50–70%. For the
following two sessions, the patient was treated with the 532 nm Qswitched
Nd-YAG laser (fluency 5 J/cm 2 ), resulting in a further
reduction in discoloration, such that most lesions were only barely
visible. Treatment was well tolerated with no adverse events and
no recurrence of pigmentation at 6 months follow-up.
Conclusion: We suggest that a combination of the Q-switched
Alexandrite and 532 Nd:YAG lasers represents a safe and
effective treatment for pigmentary sequelae of KS.
#246
American Society for Laser Medicine and Surgery Abstracts 73
SUPERFICIAL LYMPHANGIOMA TREATED WITH
FRACTIONAL ABLATIVE LASER: CLINICAL AND
REFLECTANCE CONFOCAL MICROSCOPY
EVALUATION
Thierry Passeron, Katerina Tsilika,
Jean-Philippe Lacour, Philippe Bahadoran,
Jean-Paul Ortonne
University Hospital of Nice, Nice, France
Background: Superficial lymphangiomas are benign vascular
malformations due to the dilatation of lymphangitic vessels. No
treatment approach gives actually satisfactory results. We report
a case of superficial lymphangioma treated with fractional
ablative laser.
Study: A 13-year-old boy presented with a superficial
lymphangioma of the right arm that as already recurred after a
first surgical treatment. His lymphangioma was inducing almost
permanent flow, clearly impairing his quality of life. A treatment
using fractional ablative 2,940 nm erbium laser was proposed.
After topical anesthesia with prilocaine and lidocaine cream, two
sessions of fractional erbium laser were performed at 2 months
interval (180 J/cm 2 with coagulation 4 J/cm 2 ). The evaluation was
done before treatment, 2 months after the 1st session and after 6
months follow-up. Clinical examination, digital photos and
reflectance confocal microscopy (RCM) were performed. The
number of days with flows in the months before the evaluation
was also noted.
Results: A worsening of the symptoms with daily flow was
observed in the first 15 days after the first session. Then the flows
gradually decreased. After the second session some flows were
noted three times in the 2 first months, then no more flows were
observed. Concomitantly, the number of vesicles was almost
cleared. The RCM showed before treatment numerous dark
cavities filled with low circulation flow (as compared to vascular
flow). The RCM examination performed immediately after the
laser session showed the photoablation holes down to the
superficial dermis. At 6 months follow-up, the RCM showed the
clearing of vesicles in the epidermis and superficial dermis but
noted residual lesions in the lower parts of the dermis. The
tolerance of the treatment was good and no side effect was
observed.
Conclusion: The fractional ablative erbium laser appears to be a
useful and safe treatment for superficial lymphangiomas. The
RCM examination showed residual lesions in the lower dermis
and may suggest long-term recurrences.
#247
CLINICAL EFFECTS OF GROWTH FACTOR BASED
GEL VERSUS VEHICLE IN PATIENTS TREATED
WITH A NON-ABLATIVE, FRACTIONATED
RESURFACING PROCEDURE
Jennifer Peterson, Sabrina Fabi, Mitchel Goldman
Goldman Butterwick & Associates, Cosmetic Laser Dermatology,
San Diego, CA
Background: A novel growth factor based gel generated from
neonatal human dermal fibroblasts has been demonstrated to
improve signs of photodamage including fine lines and wrinkles
following twice daily application. The primary objective was to
evaluate the efficacy and patient preference for a topical growth
factor based gel versus matched placebo combined with a
fractionated, non-ablative laser for the treatment of photoaging.
Study: We performed a double-blinded, split-face, investigator
initiated clinical study with a single study site. Fifteen patients,
skin types I–IV, received a single treatment using a fractionated
1,440 nm (7.3–8 mJ) and 1,320 nm (2.3–3 mJ) Nd:YAG in a
multiplex mode with two passes at baseline. Following the
procedure, the new skin care regimen was begun. Patients were
evaluated at 30, 60, and 90 days. Photographs were obtained at
each visit with the Canfield Vectra 3-D system. Investigator
evaluated signs of photoaging were performed at each visit based
on a 9-point scale assessing fine lines and wrinkles, coarse
wrinkles, firmness, tone, mottled hyperpigmentation, tactile
roughness, and overall photodamage for each side of the face. A 3point
investigator evaluated tolerability scale was performed at
each visit for each side of the face. At all visits, subjects evaluated
tolerability to the gels on each half of their face. At day 30, 60, and
90, 3-D photographs were compared to baseline to evaluate
global improvement. At the final visit, patient preference was
obtained.
Results: At the time of preliminary data analysis, all 15 patients,
Skin types II–IV had received treatment. This study is scheduled
to be completed by January 2011. Results will be presented at the
meeting.
Conclusion: Our preliminary analysis of patients at 30 days
suggests the addition of growth factor gel to a non-ablative
fractionated laser improves photoaging more than with a
nonablative fractionated laser alone.
#248
PH CORRELATION WITH THE DOSE OF LOW
LEVEL LASER THERAPY IN CHRONIC VENOUS
ULCER—CASE REPORT
Nathali Pinto, Mara Pereira, Carla Albhy,
Elisabeth Yoshimura, M. Cristina Chavantes
University of São Paulo, São Paulo, Brazil
Background: Venous ulceration is one of the most severe and
debilitating outcome of legs’ chronic venous insufficiency, making
up 70% of all chronic lower extremity ulcers. In the USA, 600,000
new leg ulcer cases occur yearly. The annual cost for treating
patients’ leg ulcer is estimated at some U$25 million. Lower
extremity venous ulcers’ symptoms include swelling, aching and